Kvaternick Valerie, Malinski Thomas, Wortmann Jill, Fischer James
Merial Limited, Pharmacokinetics and Drug Metabolism, 631 Route 1, North Brunswick, NJ 08902, USA.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):313-9. doi: 10.1016/j.jchromb.2007.04.037. Epub 2007 May 10.
A sensitive reversed-phase HPLC-UV method was developed for the determination of firocoxib, a novel and highly selective COX-2 inhibitor, in plasma. A 1.0 mL dog or horse plasma sample is mixed with water and passed through a hydrophobic-lipophilic copolymer solid-phase extraction column to isolate firocoxib. Quantitation is based on an external standard curve. The method has a validated limit of quantitation of 25 ng/mL and a limit of detection of 10 ng/mL. The validated upper limit of quantitation was 2500 ng/mL for horses and 10,000 ng/mL for dogs. The average recoveries ranged from 88-93% for horse plasma and 96-103% for dog plasma. The coefficient of variation in all cases was less than 10%. This method is suitable for the analysis of clinical samples from pharmacokinetic and bioequivalence studies and drug monitoring.
建立了一种灵敏的反相高效液相色谱 - 紫外法，用于测定血浆中新型高选择性环氧化酶 -2（COX-2）抑制剂氟罗昔布。取1.0 mL犬或马血浆样品与水混合，通过疏水性 - 亲脂性共聚物固相萃取柱分离氟罗昔布。定量基于外标曲线。该方法的验证定量限为25 ng/mL，检测限为10 ng/mL。马的验证定量上限为2500 ng/mL，犬为10,000 ng/mL。马血浆的平均回收率为88 - 93%，犬血浆为96 - 103%。所有情况下变异系数均小于10%。该方法适用于药代动力学和生物等效性研究以及药物监测的临床样品分析。
